Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] Group 1: Market Expansion and Challenges - Chinese pharmaceutical companies are shifting their export focus from raw materials and intermediates to innovative drugs, high-end formulations, and high-performance medical devices [2] - In the first eleven months of last year, China's pharmaceutical export value reached $100.895 billion, showing steady growth, but companies face increasing risks and challenges due to rising unilateralism and protectionism [2] - The Chinese government is encouraging regions to explore building trading platforms aimed at Southeast Asia, Central Asia, and other countries to enhance international promotion and allow more nations to benefit from China's pharmaceutical industry [2] Group 2: Cross-Border Initiatives - The China-ASEAN cross-border pharmaceutical procurement platform has successfully facilitated multiple cross-border transactions, including significant orders for domestic medical devices [3] - The China-Central Asia "Central Pharmacy" initiative has attracted innovative pharmaceutical and medical device companies to showcase over 2,200 medical devices, addressing the rigid demands of Central Asian countries [3] Group 3: Pricing Mechanisms and Support - The first overseas price registration certificate for a domestic drug treating infant vascular tumors has been issued, providing a crucial basis for companies to establish reasonable pricing in international markets [4] - The National Medical Insurance Administration is developing an international pharmaceutical pricing system that allows companies to set prices based on global market conditions rather than solely on domestic insurance payment prices [5] - A new pricing mechanism for newly launched drugs will be implemented to ensure that high-investment, high-risk innovative drugs have stable prices during their initial market entry, enhancing accessibility for quality products [5]

智通财经APP获悉，刚于 2025 年底登陆港交所的AI制药头部企业英矽智能(03696)再传捷报，继在 2026 年迎来BD"开门红"后，公司本周宣布与深圳衡泰生物签署一项总额逾 5 亿港币的研发合作协议，共同 开发协议，围绕其神经科学创新药物 ISM8969 展开全球开发合作，探索包括帕金森病在内的中枢神经 系统适应症。据公开信息，深圳衡泰生物由深圳鹏复基金与复星医药联合孵化，此次合作一定程度上延 续并加深了英矽智能与复星医药系公司的合作关系。 中枢神经系统(CNS)疾病长期以来被视为医学领域的"硬骨头"，其难点主要集中在两方面：一是发病机 制高度复杂，涉及神经元功能失衡、蛋白质异常聚集以及多条信号通路的交织紊乱；二是血脑屏障这 一"天然防线"的存在，使绝大多数药物难以有效到达脑内病灶，导致 CNS 新药研发整体失败率高、周 期长、投入大。 在 ISM8969 项目中，英矽智能依托其生成式化学引擎 Chemistry42 进行分子设计与优化，旨在实现口服 给药的前提下，兼顾对 NLRP3 靶点的抑制活性和候选分子穿透血脑屏障的能力。临床前数据表明， ISM8969 在多种神经炎症和神经退行性疾病模型中展现 ...

Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] - The successful global market entry of Chinese pharmaceutical and medical device companies requires a collaborative effort involving various departments, financial institutions, and service systems to enhance pricing power and accessibility [1][5] Group 1: Market Trends and Developments - China's pharmaceutical exports have shifted from raw materials and intermediates to innovative drugs, high-end formulations, and advanced medical devices, with a total export value of $100.895 billion in the first 11 months of last year [5] - The establishment of cross-border procurement platforms, such as the China-ASEAN procurement platform, has facilitated significant transactions, including over 10 million yuan in deals for companies like Haizheng Pharmaceutical and Qilu Pharmaceutical [6] Group 2: Pricing and Regulatory Framework - The introduction of an overseas price certification system for innovative drugs aims to provide companies with a reliable pricing reference, addressing previous issues of price information asymmetry and enhancing international market competitiveness [7] - The National Medical Insurance Administration is working on a pricing mechanism for newly launched drugs to ensure that prices reflect the high investment and risk associated with innovative products, thereby stabilizing prices during the initial market entry phase [8]

智通财经记者 | 黄华 1月上旬，据港交所信披，浙江博锐生物制药股份有限公司（文中简称"博锐生物"）已提交上市申请， 联席保荐人为华泰国际和摩根大通。 博锐生物在医药行业小有名气，它由老牌药企海正药业孵化，前身是海正药业的生物制剂业务部门，于 2019年1月起重组为有限公司。据招股书披露，PAG Highlander（太盟投资集团）及海正药业直接持股 44.62%、39.62%。 在2022年1月接受《21世纪经济报道》专访时，博锐生物时任首席执行官（CEO）王海彬表示，希望企 业会在未来成为全球性的免疫疾病领域龙头。就现阶段而言，博锐生物有不少自免药物，也确实是自 免"大药"阿达木单抗生物类似药的销冠，但距离全球龙头目标尚远，尤其是企业在创新药和国际化方面 只能说是刚刚起步。 1月7日，就博锐生物的IPO动态，智通财经向企业发送了采访邮件。截至发稿时，尚未收到回复。 是阿达木单抗国内销冠 博锐生物是国内隐形的生物药大户，代表产品为阿达木单抗（商品名：安健宁®）。 阿达木单抗是艾伯维公司开发的自免领域生物药，曾11年蝉联全球药王。凭借难以超越的商业成就，原 研商品名修美乐几乎能和药王画上等号。该产品于2003 ...

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The report highlights various sectors including trendy toys, new tobacco, home furnishings, paper packaging, personal care, AI glasses, Xiaomi Group, pet food, and AI+3D printing, indicating a mixed outlook across these industries with some showing growth potential while others face challenges Trendy Toys - The collaboration between Honor and Pop Mart to launch the first trendy toy smartphone is expected to differentiate products in a competitive market, targeting younger consumers [8] - Despite a decline in overall online GMV for trendy toys, leading companies like Miniso and Bluku are experiencing significant growth, with Miniso's blind box category growing by 315% [10] New Tobacco - The cancellation of VAT export rebates for e-cigarettes is expected to pressure profits in the short term, but may benefit companies like Smoore in the long run as they can capture market share from smaller competitors [11] - The HNB market is anticipated to expand significantly with the upcoming launch of IQOS in the US [12] Home Furnishings - The domestic real estate market remains weak, with significant declines in new and second-hand home transactions [13] - Export figures show a decline for Chinese furniture, while Vietnam's furniture exports are growing, indicating a shift in regional competitiveness [14] Paper Packaging - The report notes fluctuations in paper prices, with a general decline in prices for various paper types, but anticipates a recovery in demand as packaging needs stabilize [15] - The overall retail growth in food, beverages, and daily necessities is expected to support the packaging sector's recovery [16] Personal Care and AI Glasses - The personal care sector shows mixed performance, with some brands experiencing growth while others decline [17] - Meta's plans to significantly increase the production capacity of AI glasses signal a positive outlook for the sector, potentially boosting demand across the supply chain [18] Xiaomi Group - Xiaomi continues to lead in the smartphone market, with expectations to integrate self-developed chips and AI models into their products by 2026 [19] - The company aims to enhance its brand positioning and profitability through technological advancements and strategic product launches [20] Pet Food - The pet food market is projected to grow, with a focus on new product introductions and market expansion strategies [23] - Recent data indicates a decline in GMV for pet food on major e-commerce platforms, highlighting competitive pressures [24] AI+3D Printing - The consumer-grade 3D printing market is expected to grow, driven by new product launches and community engagement initiatives [33] - Companies are focusing on lowering entry barriers and enhancing user experience to penetrate the market further [36]

- The report introduces a "Total Heat Indicator" for monitoring market sentiment, which aggregates the heat indicators of individual stocks within broad-based indices, industries, and concepts[10][11] - The "Total Heat Indicator" is defined as the sum of the browsing, self-selection, and click counts of a stock, normalized by its market share on the same day, and then multiplied by 10,000, with a value range of [0,10000][10] - The report constructs a simple rotation strategy based on the weekly heat change rate (MA2) of broad-based indices, buying the index with the highest heat change rate at the end of each week, and staying out of the market if the "Others" group has the highest change rate[16][18] - The rotation strategy based on the heat change rate (MA2) of broad-based indices has an annualized return of 8.74% since 2017, with a maximum drawdown of 23.5%, and a return of 2.1% in 2026[19] - The report also constructs two simple portfolios based on the heat change rate of concepts, selecting the top 10 and bottom 10 stocks by total heat within the top 5 concepts with the highest heat change rate each week, and holding them equally[35] - The "BOTTOM" portfolio of low-heat stocks within high-heat concepts has historically achieved an annualized return of 15.71% with a maximum drawdown of 28.89%[37]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has been criticized by the Shanghai Stock Exchange for providing false and inaccurate financial information in its annual reports from 2021 to 2024, leading to regulatory actions against the company and its responsible personnel [3] Group 1: Regulatory Actions - The Shanghai Stock Exchange issued a public criticism against Haizheng Pharmaceutical and six related individuals due to financial inaccuracies [3] - The Zhejiang Securities Regulatory Bureau issued a warning letter to Haizheng Pharmaceutical, marking the responsible individuals in the securities and futures market integrity archives [3] - The warning letter highlighted that the company had to adjust its financial data for the years 2021 to 2024, indicating previous disclosures were misleading [3] Group 2: Financial Adjustments - The financial discrepancies were primarily due to the lack of sufficient commercial substance and rationality in the raw material trading business of its subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd. [4] - The company announced multiple adjustments to its consolidated financial statements for the years 2021 to 2023, including reductions in operating income and costs, as well as increases in investment income [4] Group 3: Business Strategy - To optimize its business structure and focus on core strengths, Haizheng Pharmaceutical plans to sell Zhejiang Pharmaceutical Industry Co., Ltd. by the end of 2025 [4] - Guangzhou Pharmaceutical Co., Ltd. has been identified as the qualified buyer, with a transfer price set at 505 million yuan [4]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has been issued warning letters due to inaccurate financial information, affecting its two former chairmen and several executives [1][2]. Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) Zhejiang Bureau issued warning letters to the company and its executives for violations of the Information Disclosure Management Measures [2]. - The company and its executives, including former chairmen Jiang Guoping and Shen Xinghu, are now recorded in the integrity archives of the securities and futures market [2]. Group 2: Financial Corrections - The company announced corrections to its financial data for the years 2021-2024, which included adjustments to operating income, operating costs, and investment income [1][4]. - The total adjustments included a reduction of operating income by 948.83 million yuan and a reduction of operating costs by 930.03 million yuan for the years 2021-2023 [4]. Group 3: Company Background - Zhejiang Haizheng Pharmaceutical is a state-owned enterprise based in Taizhou, Zhejiang, with a diverse portfolio in chemical, biological, animal, and traditional Chinese medicine [2]. - The company has been involved in financial discrepancies for four consecutive years, linked to its subsidiary Zhejiang Pharmaceutical Co., Ltd. [3]. Group 4: Business Restructuring - In December 2025, the company announced the sale of its subsidiary Zhejiang Pharmaceutical to optimize its business structure and focus on core pharmaceutical areas [4]. - The sale was confirmed with Guangzhou Pharmaceutical Co., Ltd. for a transaction price of 505 million yuan [4].

Core Viewpoint - The event "China Medical Insurance Supports Chinese Pharmaceuticals and Medical Devices Going Global" highlighted the progress of the China-ASEAN Regional Pharmaceutical Trading (Procurement) Platform, which has facilitated significant transactions in the medical sector, showcasing the potential for Chinese medical products in Southeast Asia [1] Group 1: Platform Achievements - The platform has surpassed a transaction amount of 10 million yuan in medical products [1] - Notable pharmaceutical products traded include Qilu Pharmaceutical's "Piperacillin Sodium and Tazobactam Injection," Haizheng Pharmaceutical's "Irbesartan Tablets," and Hangzhou Zhongmei Huadong's "Bailing Capsules," covering multiple Southeast Asian countries [1] - In terms of medical devices, the platform has facilitated a procurement order for a "Holmium Laser Treatment Machine" between HFM TRADING COMPANY LIMITED in Vietnam and Guangzhou Pudong Medical Equipment Co., Ltd [1] Group 2: Market Expansion - The platform has successfully assisted 16 companies in registering 53 medical devices for market entry in Vietnam [1]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. received a warning letter from the Zhejiang Securities Regulatory Bureau regarding inaccuracies in financial data from 2021 to 2024, including revenue, cost of goods sold, and investment income [1][3] Group 1: Regulatory Actions - The warning letter indicates that the company and its former executives are subject to regulatory measures due to the inaccuracies in financial reporting, which have been recorded in the securities market integrity archive [1][3] - The regulatory actions are primarily related to the company's previously disposed pharmaceutical distribution assets [1][3] Group 2: Business Adjustments - Since the new management took office, the company has made several business adjustments, including the planned transfer of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. for 500.5 million yuan [2][4] - Recent business developments include the establishment of a synthetic biology subsidiary in June 2025, a product cooperation agreement with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. in September 2025, and a joint venture with Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. in October 2025, focusing on complex injectables [2][4] Group 3: Management and Future Outlook - The current president, Xiao Weihong, assumed office in November 2023 and will become chairman in October 2024, with the financial discrepancies occurring mainly before his tenure [1][3] - Market analysts suggest that the announcement indicates that the company's historical issues have been largely resolved, reflecting a commitment to restructuring its business and focusing on core pharmaceutical operations [2][5]